Search research articles
Contact Us
Filters
Showing results (811-820 of 853) with videos related to
Page
of 86
Sort By:
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Radiology
|
August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity
Christina Messiou, Matthew Orton, Joo Ern Ang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
Peter C Fong, Timothy A Yap, David S Boss, et al.
Plos One
|
November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers
Geraldine Perkins, Timothy A Yap, Lorna Pope, et al.
ESMO Open
|
February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
J A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
R Bruno, D Hille, A Riva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
Timothy A Yap, David Olmos, Andre T Brunetto, et al.
Molecular Cancer Therapeutics
|
June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Joo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
Udai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Investigational New Drugs
|
May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies
J H M Schellens, B Heinrich, M Lehnert, et al.
Page
of 86
Search research articles
Search
Showing results (811-820 of 853) with videos related to
Sort By:
Page
of 86
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Radiology
|
August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity
Christina Messiou, Matthew Orton, Joo Ern Ang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
Peter C Fong, Timothy A Yap, David S Boss, et al.
Plos One
|
November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers
Geraldine Perkins, Timothy A Yap, Lorna Pope, et al.
ESMO Open
|
February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
J A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
R Bruno, D Hille, A Riva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
Timothy A Yap, David Olmos, Andre T Brunetto, et al.
Molecular Cancer Therapeutics
|
June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Joo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
Udai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Investigational New Drugs
|
May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies
J H M Schellens, B Heinrich, M Lehnert, et al.
Page
of 86